Anondita Medicare receives purchase order from Central Medical Services Society
Anondita Medicare · Personal Products
Key highlights
- Purchase order dated November 04, 2026, for Supply of Condoms (FS- NACO) [379] from Central Medical Services Society
- Quantity of 4,20,09,460 Pieces; 50% delivery within 90 days and balance 50% within 91 to 180 days of PO date
- Domestic entity; no promoter or promoter group interest and not a related party transaction
Why it's rated notable: The filing states a received purchase order for 4,20,09,460 pieces but gives no rupee value, so the level stays at medium without a value to compare against annual revenue of ₹137 crore.
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Bagging/Receiving of orders/contracts
Read the filing on NSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other order win filings this fortnight
- Goel Construction H1 FY27 revenue up 45.2% to ₹356.4 crore; PAT up 55.1%
- Afcons Infrastructure Ltd reports Q2 & H1 FY27 financial results and order book update
- G R Infraprojects approves unaudited results for quarter and half year ended 30 Sep 2026
- ARAPL subsidiary Humro receives US$5.47 million order for 103 autonomous robots
- Affordable Robotic & Automation Ltd subsidiary receives ₹51.8 crore order for autonomous robots
- Bhadora Industries Limited secures ₹38.64 crore order; order book crosses ₹130 crore
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- 1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.